P
ELTX icon

&Partners’s Elicio Therapeutics ELTX Stock Holding History

&Partners’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1K Hold
10,000
– – ﹤0.01% 2497
2026
Q1 		$107K Hold
10,000
– – ﹤0.01% 2336
2025
Q4 		$79.6K Hold
10,000
– – ﹤0.01% 2226
2025
Q3 		$109K Hold
10,000
– – ﹤0.01% 2045
2025
Q2 		$77.2K Buy
+10,000
New +$62.2K ﹤0.01% 1937

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

&Partners's ELTX Position: Q2 2026 in Review

&Partners held its Elicio Therapeutics (ELTX) position steady in Q2 2026 at 10,000 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2497.

&Partners first reported a position in ELTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $109K in Q3 2025. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • &Partners held 10,000 shares of Elicio Therapeutics worth $39.1K as of Q2 2026.
  • &Partners left its Elicio Therapeutics share count unchanged in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2497 holding.
  • &Partners first reported a position in Elicio Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • &Partners's Elicio Therapeutics position peaked at $109K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.